Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismLewis-Y antigen inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismImmunostimulants |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Vaccination with IGN101 in patients with non-small-cell-lung-cancer (NSCLC)
100 Clinical Results associated with Igeneon AG
0 Patents (Medical) associated with Igeneon AG
100 Deals associated with Igeneon AG
100 Translational Medicine associated with Igeneon AG